LeonaBio Competitors
| LONA Stock | 4.72 0.07 1.51% |
LeonaBio vs Dare Bioscience Correlation
Weak diversification
The correlation between LeonaBio and DARE is 0.34 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding LeonaBio and DARE in the same portfolio, assuming nothing else is changed.
Moving against LeonaBio Stock
| 0.57 | ARGX | argenx NV ADR | PairCorr |
| 0.5 | LPTV | Loop Media | PairCorr |
| 0.44 | ALNY | Alnylam Pharmaceuticals Earnings Call This Week | PairCorr |
| 0.34 | GME | GameStop Corp | PairCorr |
| 0.33 | DECAU | Denali Capital Acqui | PairCorr |
LeonaBio Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between LeonaBio and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of LeonaBio and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of LeonaBio does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between LeonaBio Stock performing well and LeonaBio Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze LeonaBio's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| LPTX | 14.85 | 6.26 | 0.64 | 1.07 | 6.90 | 25.00 | 65.13 | |||
| CTXR | 4.47 | (1.00) | 0.00 | (0.39) | 0.00 | 10.59 | 38.23 | |||
| ICU | 4.94 | (1.04) | 0.00 | (0.43) | 0.00 | 9.58 | 34.66 | |||
| APLM | 6.42 | 1.08 | 0.15 | 1.57 | 6.63 | 17.50 | 44.38 | |||
| MBRX | 4.67 | (1.30) | 0.00 | (1.63) | 0.00 | 9.37 | 41.63 | |||
| CRIS | 3.77 | (0.62) | 0.00 | (0.39) | 0.00 | 9.60 | 33.70 | |||
| FBLG | 6.02 | (0.06) | 0.00 | 0.28 | 0.00 | 14.71 | 47.13 | |||
| LNAI | 6.16 | (0.09) | 0.00 | 0.16 | 0.00 | 12.62 | 55.92 | |||
| ADTX | 10.13 | (2.79) | 0.00 | (3.16) | 0.00 | 22.54 | 63.67 | |||
| DARE | 3.03 | (0.13) | 0.00 | (0.04) | 0.00 | 6.55 | 26.52 |
Cross Equities Net Income Analysis
Compare LeonaBio and related stocks such as Leap Therapeutics, Citius Pharmaceuticals, and SeaStar Medical Holding Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CTXR | (26.3 K) | (22 K) | (31.4 K) | (1.3 M) | (2.9 M) | (8.3 M) | (10.4 M) | (12.5 M) | (15.6 M) | (17.5 M) | (23.1 M) | (33.6 M) | (32.5 M) | (39.1 M) | (37.4 M) | (33.7 M) | (32 M) |
| ICU | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (3.3 M) | (4.6 M) | (23 M) | (26.2 M) | (24.8 M) | (22.3 M) | (23.5 M) |
| APLM | (45.9 M) | (45.9 M) | (45.9 M) | (45.9 M) | (45.9 M) | (45.9 M) | (45.9 M) | (45.9 M) | (45.9 M) | (45.9 M) | (74.8 M) | (94.8 M) | (240.8 M) | (172.6 M) | (53.9 M) | (48.5 M) | (50.9 M) |
| MBRX | (748.4 K) | (748.4 K) | (748.4 K) | (748.4 K) | (748.4 K) | (748.4 K) | (3.9 M) | (9.8 M) | (11.9 M) | (13.2 M) | (17.4 M) | (15.9 M) | (29 M) | (29.8 M) | (21.8 M) | (19.6 M) | (20.6 M) |
| CRIS | (12.1 M) | (9.9 M) | (16.4 M) | (12.3 M) | (18.7 M) | (59 M) | (60.4 M) | (53.3 M) | (32.6 M) | (32.1 M) | (29.9 M) | (45.4 M) | (60.3 M) | (47.4 M) | (43.4 M) | (49.9 M) | (52.4 M) |
| FBLG | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.2 M) | (1.6 M) | (5.1 M) | (16.5 M) | (11.2 M) | (10 M) | (10.5 M) |
| LNAI | (26.7 M) | (26.7 M) | (26.7 M) | (26.7 M) | (26.7 M) | (26.7 M) | (26.7 M) | (26.7 M) | (26.7 M) | (26.7 M) | (26.7 M) | (113.4 M) | (39.7 M) | (88.4 M) | (178 M) | (160.2 M) | (152.2 M) |
| ADTX | (213 K) | (213 K) | (213 K) | (213 K) | (213 K) | (213 K) | (213 K) | (213 K) | (5.7 M) | (5.8 M) | (9.1 M) | (46.4 M) | (27.6 M) | (32.4 M) | (34.4 M) | (31 M) | (32.6 M) |
| DARE | (19.6 M) | (19.6 M) | (22.1 M) | (17.1 M) | (23.3 M) | (39.6 M) | (39.3 M) | (11.5 M) | (16.7 M) | (14.3 M) | (27.4 M) | (38.7 M) | 406.8 M | (30.2 M) | (4.1 M) | (4.7 M) | (4.4 M) |
LeonaBio and related stocks such as Leap Therapeutics, Citius Pharmaceuticals, and SeaStar Medical Holding Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in LeonaBio financial statement analysis. It represents the amount of money remaining after all of LeonaBio operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.LeonaBio Competitive Analysis
The better you understand LeonaBio competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, LeonaBio's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across LeonaBio's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
LeonaBio Competition Performance Charts
Five steps to successful analysis of LeonaBio Competition
LeonaBio's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by LeonaBio in relation to its competition. LeonaBio's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of LeonaBio in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact LeonaBio's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to LeonaBio, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your LeonaBio position
In addition to having LeonaBio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Small Blend Funds Thematic Idea Now
Small Blend Funds
Fund or Etfs that invest in stocks of small to mid-sized entities that have characteristics of both growth and value companies. The Small Blend Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Small Blend Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Check out LeonaBio Correlation with its peers. For information on how to trade LeonaBio Stock refer to our How to Trade LeonaBio Stock guide.You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of LeonaBio. Expected growth trajectory for LeonaBio significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive LeonaBio assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding LeonaBio requires distinguishing between market price and book value, where the latter reflects LeonaBio's accounting equity. The concept of intrinsic value - what LeonaBio's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push LeonaBio's price substantially above or below its fundamental value.
Understanding that LeonaBio's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether LeonaBio represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, LeonaBio's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.